Quantum Cyber N.V. Cost Of Sales
Quantum Cyber N.V. (QUCY) reported Cost Of Sales of $97.13 thousand for the 6-month period ending 2025-06-30, per its 6-K filed 2025-09-26.
Financial Statements › Expense Statement › Cost of Sales
ifrs-full:CostOfSales · last filed 2025-09-26
- Quantum Cyber N.V. cost of sales for the quarter ending 2023-12-31 was $80.03K, a 49.02% decline year-over-year.
- Quantum Cyber N.V. cost of sales for the quarter ending 2023-09-30 was $94.48K, a 20.86% increase year-over-year.
- Quantum Cyber N.V. cost of sales for the quarter ending 2023-06-30 was $100.15K, a 71.41% increase year-over-year.
- Quantum Cyber N.V. cost of sales for the quarter ending 2023-03-31 was $111.16K, a 105.34% increase year-over-year.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 6 month as first filed | Cost Of Sales 9 month | Cost Of Sales 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $97.13K 6-K · filed 2025-09-26 | ||||
| 2024-12-31 | $319.11K 20-F · filed 2025-03-31 | ||||
| 2024-06-30 | $201.74K 6-K · filed 2025-09-26 | ||||
| 2023-12-31 | $80.03K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $174.51K derived: sum of 2 quarters · filed 2025-03-31 | $274.66K derived: sum of 3 quarters · filed 2025-03-31 | $385.82K 20-F · filed 2025-03-31 | |
| 2023-09-30 | $94.48K 6-K · filed 2023-11-16 | $194.63K derived: sum of 2 quarters · filed 2023-11-16 | $305.79K 6-K · filed 2023-11-16 | $462.78K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-06-30 | $100.15K 6-K · filed 2023-08-15 | $211.31K 6-K · filed 2024-10-18 | $368.30K derived: sum of 3 quarters · filed 2025-03-31 | $446.47K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-03-31 | $111.16K 6-K · filed 2023-05-16 | $268.15K derived: sum of 2 quarters · filed 2025-03-31 | $346.33K derived: sum of 3 quarters · filed 2025-03-31 | $404.75K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2022-12-31 | $156.99K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $235.16K derived: sum of 2 quarters · filed 2025-03-31 | $293.59K derived: sum of 3 quarters · filed 2025-03-31 | $347.73K 20-F · filed 2025-03-31 | |
| 2022-09-30 | $78.18K 6-K · filed 2023-11-16 | $136.60K derived: sum of 2 quarters · filed 2023-11-16 | $190.74K 6-K · filed 2023-11-16 | ||
| 2022-06-30 | $58.43K 6-K · filed 2023-08-15 | $112.56K 6-K · filed 2023-08-15 | $119.00K 6-K · filed 2022-09-07 | ||
| 2022-03-31 | $54.14K 6-K · filed 2023-05-16 | ||||
| 2021-12-31 | $399.73K 20-F · filed 2024-04-09 | ||||
| 2021-06-30 | $64.77K 6-K · filed 2022-09-07 | ||||
| 2020-12-31 | $370.48K 20-F · filed 2023-04-07 | ||||
| 2019-12-31 | $342.66K 20-F · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |